JOURNAVX is the brand name for suzetrigine, an oral medicine FDA-approved for moderate to severe acute pain in adults. It is a non-opioid option and is not an NSAID.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
JOURNAVX is the brand name for suzetrigine, an oral medicine FDA-approved for moderate to severe acute pain in adults. It is a non-opioid option and is not an NSAID. A consultation evaluates the cause of pain and whether this medicine is appropriate within a broader recovery plan.
Suzetrigine blocks NaV1.8 sodium channels involved in pain signaling in peripheral nerves. It does not work through opioid receptors. A different mechanism does not make it risk-free or suitable for every pain condition. The evidence for an acute-pain indication cannot be presented as proven treatment for chronic pain or neuropathy reversal.
A clinician considers the diagnosis, expected duration, other treatment options and health history. The labeled use is in adults; pediatric safety and effectiveness are not established. Liver impairment, pregnancy or breastfeeding and a complete medicine review can affect the decision. An appointment does not guarantee a prescription.
Explain the pain timeline, injury or procedure and prior treatment. The clinician discusses likely benefit, limitations and a short treatment and reassessment plan. If prescribed, follow the actual prescription and current medication guide. A website should not provide a personalized starting dose or conversion from another pain medicine.
Bring all prescription, nonprescription and herbal products and relevant discharge records. Ask the pharmacist to check interactions. Tell the clinician if you take a strong CYP3A inhibitor or inducer. Do not stop or replace an existing treatment without coordination.
Strong CYP3A inhibitors are contraindicated, and other CYP3A medicines can require changes or avoidance. Avoid grapefruit during treatment. The label recommends the shortest appropriate duration and notes that treatment beyond 14 days has not been studied. Severe or changing pain can require urgent evaluation even when medication provides some relief.
Review function and recovery as well as pain intensity. Contact the clinician for side effects or worsening pain. If pain persists, reassess the diagnosis and treatment rather than assuming repeated courses are supported. The surgical team should remain involved in postoperative problems.
Confirm clinician assessment capability, actual pharmacy availability and the medicine's price and authorization requirements. Coverage and cost depend on the prescription, pharmacy and exact plan. Discuss the diagnosed cause of pain; an approval for acute pain does not establish effectiveness for chronic pain.
Yes. A new pain medicine does not explain the cause of pain. An examination and, when indicated, tests help distinguish a minor problem from an injury or illness needing other treatment. Tell the clinician where pain began, any injury, prior treatment and new weakness, fever or other concerning symptoms. Severe or rapidly worsening symptoms need urgent assessment.
Journavx contains suzetrigine, a nonopioid pain medicine that targets NaV1.8 sodium channels involved in pain signaling. It is not an NSAID and is not a controlled substance. Those distinctions do not mean it suits every patient or can be combined with every other medicine.
Journavx is labeled for moderate to severe acute pain in adults. Use beyond 14 days has not been studied under the label. It is not established as indefinite treatment for chronic back pain or ongoing neuropathic pain. Chronic pain needs assessment of the cause, function and a continuing treatment plan. Ask about separate visit and medicine costs before choosing care.
Give the prescriber and pharmacist a complete medicine and supplement list before Journavx. Strong CYP3A inhibitors are contraindicated, and other interacting medicines may require avoidance or a different plan. Avoid grapefruit and grapefruit juice during treatment. Do not combine products or change existing prescriptions without the clinician's instructions.
Relief varies with the cause and severity of pain; an exact onset or complete relief cannot be promised. Review adverse effects and interacting medicines with the prescriber. Nonopioid does not mean a person is always safe to drive: pain, other medicines or symptoms can still impair function. Contact the clinician if pain persists or worsens.
Check Journavx coverage with the pharmacy benefit for your exact plan. Ask about formulary status, prior authorization, copay and pharmacy availability separately from the office visit. Medicare or an insurer's name does not establish coverage for every product. An authorization request can be denied or delayed.
Ask the dispensing pharmacy for the current price of the prescribed course and ask your exact plan about its pharmacy benefit, formulary and authorization requirements. The visit fee, medicine, follow-up and any assessment tests are separate possible charges. An insurer’s name or a manufacturer assistance program does not guarantee your eligibility or a fixed copay. Confirm the actual pharmacy supply, authorization and out-of-pocket cost before arranging the course. The clinician should decide whether the medicine fits the acute-pain problem before cost or a brand request determines the plan.
In the label’s adult postoperative trials, median time from dosing to meaningful pain relief was 119 minutes in the abdominoplasty study. It was 240 minutes in the bunion-surgery study. Those study medians do not predict an individual’s onset or guarantee complete relief. Journavx is a nonopioid medicine, but that does not mean sleepiness is impossible: somnolence was reported in the open-label acute-pain study. Pain, illness and other medicines can also affect alertness. Do not drive or do hazardous work when drowsy or impaired. Ask the prescriber when to reassess inadequate relief or side effects. Its adult acute-pain indication does not establish ongoing chronic-pain treatment.
Follow your own prescription and the pharmacist’s instructions. Take the labeled first dose on an empty stomach, at least 1 hour before or 2 hours after food. Food can delay its start of pain relief. Later doses can be taken with or without food. Swallow tablets whole and avoid grapefruit during treatment. Liver impairment and interacting medicines can change the plan, so do not copy another patient’s dose schedule. Strong CYP3A inhibitors are contraindicated. Ask what to do if a dose is missed and when treatment should stop. Use beyond 14 days for acute pain has not been studied.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
